● Home  

● Random  

● Nearby  



● Log in  



● Settings  



● Donate  



● About Wikipedia  

● Disclaimers  



Wikipedia





Empagliflozin/metformin





● Article  
● Talk  


● Language  

● Watch  

● Edit  





Empagliflozin/metformin, sold under the brand name Synjardy among others, is a fixed-dose combination anti-diabetic medication used to treat type 2 diabetes. It contains empagliflozin and metformin hydrochloride.[4][5] It is taken by mouth.[4][5]

Empagliflozin/metformin
Combination of
EmpagliflozinSGLT2 inhibitor
Metformin HydrochlorideAnti-diabetic biguanide
Clinical data
Trade namesSynjardy, Jardiamet
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
    • Routes of
    administration    		By mouth
    ATC code
    Legal status
    Legal status
    • AU: S4 (Prescription only)[2]
  • UK: POM (Prescription only)[3]
  • US: ℞-only[4]
  • EU: Rx-only[5]
    • Identifiers
    PubChem CID
    KEGG
    ChEBI
    Chemical and physical data
    FormulaC27H39Cl2N5O7
    Molar mass616.54 g·mol−1
    3D model (JSmol)

    • CN(C)C(=N)N=C(N)N.COC1C(C(C(C(O1)C2=CC(=C(C=C2)Cl)CC3=CC=C(C=C3)OC4CCOC4)O)O)O.Cl

    • InChI=1S/C23H27ClO7.C4H11N5.ClH/c1-28-23-21(27)19(25)20(26)22(31-23)14-4-7-18(24)15(11-14)10-13-2-5-16(6-3-13)30-17-8-9-29-12-17;1-9(2)4(7)8-3(5)6;/h2-7,11,17,19-23,25-27H,8-10,12H2,1H3;1-2H3,(H5,5,6,7,8);1H/t17-,19+,20+,21-,22-,23-;;/m0../s1

    • Key:YBRWIMHXUHRVDV-ZBYKXHQASA-N

    The most common side effects include hypoglycaemia (low blood sugar levels) when the medicine is taken with a sulphonylurea or insulin, infections of the urinary tract and genitals, and increased urination.[5]

    It was approved for use in the European Union in May 2015,[5] for use in the United States in August 2015,[6] and for use in Australia in May 2020.[2] In 2020, it was the 238th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8] It is available as a generic medication.[9]

    Medical uses

    edit

    In the European Union empagliflozin/metformin is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control:[5]

    In the United States it is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.[4]

    In June 2023, the US Food and Drug Administration (FDA) expanded the indication, as an addition to diet and exercise, to improve blood sugar control in children 10 years and older with type 2 diabetes.[10]

    Society and culture

    edit
    edit

    Empagliflozin/metformin was approved for use in the European Union in May 2015.[5]

    Empagliflozin/metformin was approved for use in the United States in August 2015.[6][11] The extended release version was approved for use in the United States in December 2016.[12][13]

    Empagliflozin/metformin was approved for use in Australia in May 2020.[2]

    References

    edit
    1. ^ "Empagliflozin / metformin Use During Pregnancy". Drugs.com. 10 September 2019. Retrieved 11 February 2020.
  • ^ a b c "Summary for ARTG Entry: 229815 Jardiamet 5 mg / 500 mg empagliflozin/metformin hydrochloride 5mg/500mg film coated tablet blister pack". Therapeutic Goods Administration (TGA).[permanent dead link]
  • ^ "Synjardy film coated tablets - Summary of Product Characteristics (SmPC)". (emc). 23 October 2019. Retrieved 10 February 2020.
  • ^ a b c d "Synjardy XR- empagliflozin, metformin hydrochloride tablet, extended release". DailyMed.
  • ^ a b c d e f g h i j "Synjardy EPAR". European Medicines Agency (EMA). 17 September 2018. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  • ^ a b "Synjardy (empagliflozin and metformin hydrochloride) Tablets". U.S. Food and Drug Administration (FDA). 4 August 2016. Retrieved 10 February 2020.
  • ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  • ^ "Empagliflozin; Metformin - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  • ^ "2022 First Generic Drug Approvals". U.S. Food and Drug Administration (FDA). 3 March 2023. Archived from the original on 30 June 2023. Retrieved 30 June 2023.
  • ^ "FDA Approves New Class of Medicines to Treat Pediatric Type 2 Diabetes". U.S. Food and Drug Administration (FDA) (Press release). 20 June 2023. Retrieved 20 June 2023.
  • ^ "Synjardy: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 10 February 2020.
  • ^ "Synjardy XR (empagliflozin and metformin hydrochloride extended-release) Tablets". U.S. Food and Drug Administration (FDA). 26 October 2017. Retrieved 10 February 2020.
  • ^ "Synjardy XR: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 11 February 2020.
    • Retrieved from "https://en.wikipedia.org/w/index.php?title=Empagliflozin/metformin&oldid=1224807133"




    Last edited on 20 May 2024, at 15:43  





    Languages

     



    This page is not available in other languages.
      

     Wikipedia


    ●This page was last edited on 20 May 2024, at 15:43 (UTC).
    ●Content is available under CC BY-SA 4.0 unless otherwise noted.


    ●Privacy policy
    ●About Wikipedia
    ●Disclaimers
    ●Contact Wikipedia
    ●Code of Conduct
    ●Developers
    ●Statistics
    ●Cookie statement
    ●Terms of Use
    ●Desktop